HALO SEC Filings, Earnings & Splits

Halozyme Therapeutics filed a 10-Q that includes an exhibit adopting its 2021 Employee Stock Purchase Plan, which allows eligible employees to purchase company stock through payroll deductions.

Halozyme reported Q3 2026 results with total revenue up 39% YoY to $493 million and royalty revenue up 44% to $341 million, and raised its full-year 2026 financial guidance across revenue, EBITDA, and EPS. The company also highlighted an expanded ENHANZE collaboration with three partners and a Dutch patent court injunction against Merck's Keytruda Qlex.

Halozyme Therapeutics elected James Daly to its Board of Directors on September 28, 2026. He will serve in the class of directors with terms ending at the 2029 annual meeting and was not initially assigned to any Board committee.

Halozyme Therapeutics completed a $1.5 billion offering of 1.50% Convertible Senior Notes due 2033, including the full exercise of the initial purchasers' option to purchase an additional $200 million. The company used net proceeds to fund capped call transactions, repurchase existing convertible notes, and for general corporate purposes.

Halozyme Therapeutics priced an upsized $1.3 billion private offering of 1.50% convertible senior notes due 2033, with an option for an additional $200 million. Proceeds will be used to fund capped call transactions, repurchase existing convertible notes, and for general corporate purposes.

Halozyme Therapeutics announced a proposed offering of $1.05 billion in convertible senior notes due 2033, with an option for an additional $150 million. The company plans to use proceeds to fund capped call transactions, repurchase existing convertible notes, and for general corporate purposes.

Dannielle Appelhans was elected to the Board of Directors of Halozyme Therapeutics, Inc. on August 14, 2026, with a term ending at the 2028 annual meeting.